Last reviewed · How we verify
NCT06842589
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
Phase 1 trial testing anti-CD19 CAR-T cells in Multi-Drug Resistant Nephrotic Syndrome in 18 participants. Currently enrolling.
14 February 2027
Quick facts
| Lead sponsor | The Children's Hospital of Zhejiang University School of Medicine |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 14 May 2025 |
| Primary completion | 14 February 2027 |
| Estimated completion | 31 January 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- anti-CD19 CAR-T cells
Conditions studied
- Multi-Drug Resistant Nephrotic Syndrome — all drugs for Multi-Drug Resistant Nephrotic Syndrome →
- CAR-T Cell Therapy — all drugs for CAR-T Cell Therapy →
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Who can join
2 and older, any sex, with Multi-Drug Resistant Nephrotic Syndrome or CAR-T Cell Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of patients with Multi-drug resistant SRNS
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.
Jin Y, Xie Y, Fu H, Liu F, et al · · 2025 · cited 2× · PMID 41007627 · DOI 10.3390/biomedicines13092063
Verify or expand the search:
- PubMed search for NCT06842589
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of anti-CD19 CAR-T cells
Trials testing the same drug.
- NCT06821659 — Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory · Phase 1, PHASE2 · not yet recruiting
- NCT06792344 — Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis · Phase 1 · recruiting
- NCT04545762 — Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · recruiting
Other recruiting trials for Multi-Drug Resistant Nephrotic Syndrome
Currently open trials in the same condition.
- NCT06792799 — Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease · EARLY_PHASE1 · recruiting
- NCT06553898 — Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS · Phase 1 · recruiting
Other The Children's Hospital of Zhejiang University School of Medicine trials
Trials by the same sponsor.
- NCT07368504 — AI for Newborn Metabolic Screening · NA · not yet recruiting
- NCT07499154 — Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery · Phase 4 · not yet recruiting
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07496541 — Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis · not yet recruiting
- NCT07045844 — Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06842589 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Children's Hospital of Zhejiang University School of Medicine
- Last refreshed: 7 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06842589.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing